Stock data
Starling Oncology, Inc. (STLN)
Starling Oncology, Inc. (STLN) reported revenue of US$502.73M and net income of -US$60.61M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$502.73M | — | -US$36.08M | -US$60.61M | — |
| 2024 | US$393.41M | — | -US$60.12M | -US$64.66M | — |
| 2023 | US$324.24M | — | -US$77.02M | -US$83.07M | — |
| 2022 | US$252.48M | — | -US$81.95M | US$0.15M | — |
| 2021 | US$203.00M | — | -US$45.86M | -US$10.93M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$161.28M | -US$9.79M | — |
| 2026-03-31 | US$147.44M | -US$2.49M | — |
| 2025-12-31 | US$141.96M | -US$7.51M | — |
| 2025-09-30 | US$136.56M | -US$16.50M | — |
| 2025-06-30 | US$119.80M | -US$17.01M | — |
| 2025-03-31 | US$104.41M | -US$19.59M | — |
| 2024-12-31 | US$100.27M | -US$13.18M | — |
| 2024-09-30 | US$99.90M | -US$16.11M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.